Katina C Calakos1, Shivani Bhatt1, Dawn W Foster2,3, Kelly P Cosgrove1,2,4. 1. Department of Neuroscience, Yale University, New Haven, CT. 2. Department of Psychiatry, Yale University, New Haven, CT. 3. School of Public Health, Yale University, New Haven, CT. 4. PET Center, Radiology and Biomedical Imaging, Yale University, New Haven, CT.
Abstract
PURPOSE OF THE REVIEW: Cannabis is the most commonly used illicit substance worldwide. In recent decades, highly concentrated products have flooded the market, and prevalence rates have increased. Gender differences exist in cannabis use, as men have higher prevalence of both cannabis use and cannabis use disorder (CUD), while women progress more rapidly from first use to CUD. This paper reviews findings from preclinical and human studies examining the sex-specific neurobiological underpinnings of cannabis use and CUD, and associations with psychiatric symptoms. RECENT FINDINGS: Sex differences exist in the endocannabinoid system, in cannabis exposure effects on brain structure and function, and in the co-occurrence of cannabis use with symptoms of anxiety, depression and schizophrenia. In female cannabis users, anxiety symptoms correlate with larger amygdala volume and social anxiety disorder symptoms correlate with CUD symptoms. Female cannabis users are reported to be especially vulnerable to earlier onset of schizophrenia, and mixed trends emerge in the correlation of depressive symptoms with cannabis exposure in females and males. SUMMARY: As prevalence of cannabis use may continue to increase given the shifting policy landscape regarding marijuana laws, understanding the neurobiological mechanisms of cannabis exposure in females and males is key. Examining these mechanisms may help inform future research on sex-specific pharmacological and behavioral interventions for women and men with high-risk cannabis use, comorbid psychiatric disease, and CUD.
PURPOSE OF THE REVIEW: Cannabis is the most commonly used illicit substance worldwide. In recent decades, highly concentrated products have flooded the market, and prevalence rates have increased. Gender differences exist in cannabis use, as men have higher prevalence of both cannabis use and cannabis use disorder (CUD), while women progress more rapidly from first use to CUD. This paper reviews findings from preclinical and human studies examining the sex-specific neurobiological underpinnings of cannabis use and CUD, and associations with psychiatric symptoms. RECENT FINDINGS: Sex differences exist in the endocannabinoid system, in cannabis exposure effects on brain structure and function, and in the co-occurrence of cannabis use with symptoms of anxiety, depression and schizophrenia. In female cannabis users, anxiety symptoms correlate with larger amygdala volume and social anxiety disorder symptoms correlate with CUD symptoms. Female cannabis users are reported to be especially vulnerable to earlier onset of schizophrenia, and mixed trends emerge in the correlation of depressive symptoms with cannabis exposure in females and males. SUMMARY: As prevalence of cannabis use may continue to increase given the shifting policy landscape regarding marijuana laws, understanding the neurobiological mechanisms of cannabis exposure in females and males is key. Examining these mechanisms may help inform future research on sex-specific pharmacological and behavioral interventions for women and men with high-risk cannabis use, comorbid psychiatric disease, and CUD.
Entities:
Keywords:
Cannabis; Cannabis Use Disorder; Psychiatric Comorbidity; Sex Differences
Authors: M López-Gallardo; A B López-Rodríguez; Á Llorente-Berzal; D Rotllant; K Mackie; A Armario; R Nadal; M-P Viveros Journal: Neuroscience Date: 2011-10-06 Impact factor: 3.590
Authors: Guoqiang Xing; Janis Carlton; Lei Zhang; Xiaolong Jiang; Carol Fullerton; He Li; Robert Ursano Journal: Neurosci Lett Date: 2011-05-11 Impact factor: 3.046
Authors: M Herkenham; A B Lynn; M D Little; M R Johnson; L S Melvin; B R de Costa; K C Rice Journal: Proc Natl Acad Sci U S A Date: 1990-03 Impact factor: 11.205
Authors: Lesia M Ruglass; Adriana Espinosa; Skye Fitzpatrick; M Kamran Meyer; Kechna Cadet; Alexander Sokolovsky; Kristina M Jackson; Helene R White Journal: Subst Use Misuse Date: 2019-10-01 Impact factor: 2.164
Authors: Amanda R Bolbecker; Deborah Apthorp; Ashley Schnakenberg Martin; Behdad Tahayori; Leah Moravec; Karen L Gomez; Brian F O'Donnell; Sharlene D Newman; William P Hetrick Journal: Drug Alcohol Depend Date: 2018-06-21 Impact factor: 4.492
Authors: Alexandra Venegas; Lindsay R Meredith; ReJoyce Green; Ziva D Cooper; Lara A Ray Journal: Exp Clin Psychopharmacol Date: 2020-07-13 Impact factor: 3.157
Authors: Erin L Thompson; Ileana Pacheco-Colón; Sarah M Lehman; Ashley R Adams; Samuel W Hawes; Dayana C Paula; Karen Granja; William J Pulido; Raul Gonzalez Journal: Drug Alcohol Depend Date: 2021-09-22 Impact factor: 4.492
Authors: Dennis J Sholler; Justin C Strickland; Tory R Spindle; Elise M Weerts; Ryan Vandrey Journal: Addict Biol Date: 2020-09-28 Impact factor: 4.280
Authors: Christina M Ruiz; Alexa Torrens; Erik Castillo; Christina R Perrone; Jenny Cevallos; Victoria C Inshishian; Eden V Harder; Drew N Justeson; Marilyn A Huestis; Vivek Swarup; Daniele Piomelli; Stephen V Mahler Journal: Neuropsychopharmacology Date: 2020-09-14 Impact factor: 7.853